ATE292631T1 - Verfahren zu herstellung von 1,3-oxathiolane nukleosiden - Google Patents

Verfahren zu herstellung von 1,3-oxathiolane nukleosiden

Info

Publication number
ATE292631T1
ATE292631T1 AT03077251T AT03077251T ATE292631T1 AT E292631 T1 ATE292631 T1 AT E292631T1 AT 03077251 T AT03077251 T AT 03077251T AT 03077251 T AT03077251 T AT 03077251T AT E292631 T1 ATE292631 T1 AT E292631T1
Authority
AT
Austria
Prior art keywords
oxathiolane
producing
oxathiolane nucleosides
preparation
nucleosides
Prior art date
Application number
AT03077251T
Other languages
English (en)
Inventor
Darryl Cleary
Jose Soria
George R Painter
Dennis C Liotta
Merrick Almond
Marcos Luis Sznaidman
Original Assignee
Gilead Sciences Inc
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Univ Emory filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE292631T1 publication Critical patent/ATE292631T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
AT03077251T 1998-08-12 1999-08-12 Verfahren zu herstellung von 1,3-oxathiolane nukleosiden ATE292631T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9621498P 1998-08-12 1998-08-12
US12284199P 1999-03-04 1999-03-04

Publications (1)

Publication Number Publication Date
ATE292631T1 true ATE292631T1 (de) 2005-04-15

Family

ID=26791450

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99943712T ATE282034T1 (de) 1998-08-12 1999-08-12 Verfahren zur herstellung von 1,3- oxathiolannukleoside
AT03077251T ATE292631T1 (de) 1998-08-12 1999-08-12 Verfahren zu herstellung von 1,3-oxathiolane nukleosiden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99943712T ATE282034T1 (de) 1998-08-12 1999-08-12 Verfahren zur herstellung von 1,3- oxathiolannukleoside

Country Status (17)

Country Link
US (4) US6215004B1 (de)
EP (4) EP1361223B1 (de)
JP (4) JP4249393B2 (de)
KR (3) KR100856416B1 (de)
CN (1) CN1141305C (de)
AT (2) ATE282034T1 (de)
AU (2) AU771779B2 (de)
BR (1) BR9912951B1 (de)
CA (3) CA2340214C (de)
DE (2) DE69924651D1 (de)
ES (2) ES2537540T3 (de)
HK (2) HK1038921A1 (de)
IL (4) IL141359A0 (de)
MX (1) MXPA01001552A (de)
PT (2) PT1104415E (de)
RU (2) RU2244712C2 (de)
WO (1) WO2000009494A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
KR100856416B1 (ko) * 1998-08-12 2008-09-04 길리애드 사이언시즈, 인코포레이티드 1,3-옥사티올란 뉴클레오시드의 제조 방법
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
AU2002335489B2 (en) * 2001-03-01 2008-06-05 Abbott Laboratories Polymorphic and other crystalline forms of cis-FTC
WO2002102796A1 (en) * 2001-06-15 2002-12-27 Shire Biochem Inc. Stereoselective method for the preparation of nucleoside analogues
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
US20030162992A1 (en) * 2001-12-14 2003-08-28 Watanabe Kyoichi A. Preparation of intermediates useful in the synthesis of antiviral nucleosides
BR0312802A (pt) * 2002-07-19 2005-04-19 Michael E Garst Pró-drogas de inibidores de bombas de próton
US6855821B2 (en) 2002-08-06 2005-02-15 Pharmasset, Ltd. Processes for preparing 1,3-dioxolane nucleosides
US20040224917A1 (en) * 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2005056870A1 (ja) * 2003-12-09 2005-06-23 Asahi Glass Company, Limited 可視光で光触媒活性を有するＴｉ酸化物膜およびその製造方法
CN105039489A (zh) * 2004-02-03 2015-11-11 埃莫里大学 制备1,3-二氧戊环核苷的方法
WO2008053496A2 (en) * 2006-10-30 2008-05-08 Lupin Limited An improved process for the manufacture of cis (-)-lamivudine
US8318934B2 (en) * 2007-09-28 2012-11-27 Avexa Limited Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes
EP2050757A1 (de) * 2007-10-10 2009-04-22 Cilag AG Verfahren zur Herstellung von 2' -deoxy-5-Azacytidin (Decitabin)
EP2048151A1 (de) * 2007-10-10 2009-04-15 Cilag AG Verfahren zur Herstellung von Nukleosiden durch direkte Glykosidation der Nukleosidbase
US20110288298A1 (en) * 2008-11-12 2011-11-24 Lupin Limited novel polymorph of emtricitabine and a process for preparing of the same
WO2010082128A1 (en) 2009-01-19 2010-07-22 Aurobindo Pharma Limited Process for the preparation of cis-nucleoside derivative
EP2454244B1 (de) 2009-07-15 2013-06-26 Lupin Limited Verbessertes verfahren zur herstellung von efavirenz
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
US20130296562A1 (en) 2011-08-05 2013-11-07 Lupin Limited Stereoselective process for preparation of 1,3-oxathiolane nucleosides
CN106478618A (zh) * 2016-10-14 2017-03-08 上海礼泰医药科技有限公司 恩曲他滨氢卤酸盐的制备方法
CN109553610B (zh) * 2018-12-21 2020-10-27 江西富祥药业股份有限公司 一种恩曲他滨异构体的制备方法
CN115043823A (zh) * 2022-06-28 2022-09-13 江苏普信制药有限公司 一种恩曲他滨的合成方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5587480A (en) 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5248776A (en) 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
SK279542B6 (sk) 1991-03-06 1998-12-02 The Wellcome Foundation Limited U
IT1244501B (it) 1991-03-22 1994-07-15 Sigma Tau Ind Farmaceuti Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9311709D0 (en) 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
US5633320A (en) 1994-07-08 1997-05-27 Mitsui Petrochemical Industries, Ltd. Thermoplastic polyester resin composition
GB9506644D0 (en) 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
GB9525606D0 (en) * 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
TW318283B (en) 1996-12-09 1997-10-21 United Microelectronics Corp Multi-level read only memory structure and manufacturing method thereof
KR100856416B1 (ko) * 1998-08-12 2008-09-04 길리애드 사이언시즈, 인코포레이티드 1,3-옥사티올란 뉴클레오시드의 제조 방법
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9109124B2 (en) 2011-06-01 2015-08-18 Xerox Corporation Solid ink compositions comprising semicrystalline oligomer resins
JP5800924B2 (ja) 2014-01-20 2015-10-28 ファナック株式会社 回転工具の回転振れ及び動バランス調整機構

Also Published As

Publication number Publication date
EP1361223A1 (de) 2003-11-12
BR9912951B1 (pt) 2012-01-10
KR100856416B1 (ko) 2008-09-04
RU2439069C2 (ru) 2012-01-10
JP2002522534A (ja) 2002-07-23
IL201293A (en) 2011-02-28
KR20070094667A (ko) 2007-09-20
DE69924651D1 (de) 2005-05-12
EP1104415B1 (de) 2004-11-10
HK1156604A1 (en) 2012-06-15
AU771779B2 (en) 2004-04-01
JP5547772B2 (ja) 2014-07-16
PT1104415E (pt) 2005-03-31
EP1104415A1 (de) 2001-06-06
ES2232169T3 (es) 2005-05-16
US6576776B1 (en) 2003-06-10
CN1313858A (zh) 2001-09-19
AU2004202930B2 (en) 2008-05-08
CA2563022C (en) 2010-11-23
CA2714085A1 (en) 2000-02-24
ES2537540T3 (es) 2015-06-09
CA2714085C (en) 2013-02-05
KR20060063991A (ko) 2006-06-12
US6518425B1 (en) 2003-02-11
EP1361223B1 (de) 2005-04-06
IL141359A0 (en) 2002-03-10
EP2322518B1 (de) 2015-02-25
US20030144532A1 (en) 2003-07-31
IL201293A0 (en) 2010-05-31
RU2004125183A (ru) 2006-01-27
US6939965B2 (en) 2005-09-06
DE69921829T2 (de) 2005-10-27
US6215004B1 (en) 2001-04-10
JP2012176974A (ja) 2012-09-13
KR20010072428A (ko) 2001-07-31
HK1038921A1 (en) 2002-04-04
JP5203897B2 (ja) 2013-06-05
WO2000009494A1 (en) 2000-02-24
RU2244712C2 (ru) 2005-01-20
PT2322518E (pt) 2015-06-08
CN1141305C (zh) 2004-03-10
AU2004202930A1 (en) 2004-07-29
DE69921829D1 (de) 2004-12-16
CA2340214C (en) 2007-10-30
IL173745A0 (en) 2006-07-05
ATE282034T1 (de) 2004-11-15
KR101208429B1 (ko) 2012-12-05
EP1535921A1 (de) 2005-06-01
AU2004202930C1 (en) 2008-11-13
BR9912951A (pt) 2001-10-02
EP2322518A1 (de) 2011-05-18
JP2014132026A (ja) 2014-07-17
AU5675299A (en) 2000-03-06
CA2340214A1 (en) 2000-02-24
IL173745A (en) 2010-05-31
MXPA01001552A (es) 2004-08-23
JP2009108080A (ja) 2009-05-21
JP5956492B2 (ja) 2016-07-27
IL141359A (en) 2006-07-05
CA2563022A1 (en) 2000-02-24
JP4249393B2 (ja) 2009-04-02
KR100687194B1 (ko) 2007-02-27

Similar Documents

Publication Publication Date Title
ATE292631T1 (de) Verfahren zu herstellung von 1,3-oxathiolane nukleosiden
ATE277937T1 (de) Verfahren zur herstellung von 9-(2- (diethylphosphonomethoxy)ethyl)-adenin
ATE360608T1 (de) Verfahren zur herstellung von 1,3-diolen
ATE334136T1 (de) Verfahren zur herstellung von azithromycin
DE3764602D1 (de) Verfahren zur herstellung von n,n-diaryl-harnstoffen.
DE3750087D1 (de) Dekorblatt, sowie verfahren zur herstellung desselben.
DE3772590D1 (de) Verfahren zur herstellung von 1,4-dihydropyridin-derivaten.
DE59912242D1 (de) Verfahren zur herstellung von (s,s)-benzyl-2,8-diazabicyclo(4.3.0)nonan
DE68923171D1 (de) Aluminiumhydroxyd, verfahren zur herstellung und zusammensetzung.
ATE483691T1 (de) Verfahren zur herstellung von unsymmetrischen 4,6-bis(aryloxy)pyrimidin-derivaten
DE59001006D1 (de) Verfahren zur herstellung von 1,1,1,2-tetrafluorethan.
DE59001106D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2-chlorethan.
DE69106370D1 (de) Verfahren zur herstellung von werkzeugen und matrizen.
DE69707175T2 (de) Verfahren zur Herstellung von nicht symmetrischen 4,6-Bis(aryloxy)-Pyrimidinverbindungen
DE3778442D1 (de) Verfahren zur herstellung von metallfluoriden, verwendbar zur herstellung von fluorid-glaesern.
ATE366251T1 (de) Verfahren zur herstellung von 1,3- disubstituierten-4-oxocyclischen harnstoffen
DE3779247D1 (de) Verfahren zur herstellung von 2,3,5-trimethylhydrochinon.
ATE209636T1 (de) Verbessertes verfahren zur herstellung von unsymmetrischen 4,6- bis(aryloxy)pyrimidinverbindungen
DE3871591D1 (de) Verfahren zur herstellung von 1-propargyl-2,4-dioxoimidazolidin.
DE69801454D1 (de) Verfahren zur Herstellung von 2-Methyl-1,4-Benzochinon
DE3770059D1 (de) Verfahren zur herstellung von 4,4'-bis-phenol.
DE3668318D1 (de) Verfahren zur herstellung von chlor- bzw. bromacetaldehyd-acetalen.
ATE241619T1 (de) Verfahren zur herstellung von nukleosid-analogen
ATE61584T1 (de) Verfahren zur herstellung von 2,4-diamino-3-oxy- pyrimidin-derivaten.
DE3673662D1 (de) Verfahren zur herstellung von pyrimidin und 2-alkylpyrimidin.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties